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Abstract
Use of terlipressin in septic shock relies on a series of European
studies resulting in a better knowledge of this vasopressive agent.
Additional studies demonstrate that this agent appears to have
attractive properties when administered properly. In comparison to
prior reports, continuous infusion of low-dose terlipressin seems
superior when administered to septic animals. For the first time in
humans, Morelli and colleagues compared this mode of adminis-
tration with other vasopressors.
In the previous issue of Critical Care, a European group
made a new contribution to the terlipressin literature [1]. For
the first time, terlipressin, vasopressin, and norepinephrine
were compared among patients with septic shock. Because
vasopressin is not available in most European countries,
terlipressin, a vasopressin analog, was used in patients with
norepinephrine-resistant septic shock. Terlipressin is initially
indicated in patients with hepatorenal syndrome and bleeding
esophageal varices. In 2001, a German group showed its
efficacy in endotoxemic sheep [2]. In 2002, a British group
treated eight patients with norepinephrine-resistant septic
shock by repeated bolus administration of terlipressin [3]. In
2004, studies from France, Spain, and Italy confirmed the
feasibility of terlipressin in septic shock [4-6].
Vasopressin and its analogs act on three subtypes of
receptors: V1, V2, and V3 [7]. V1 receptors are found on
various cells, including vascular smooth muscle cells, causing
vasoconstriction. V2 receptors are expressed by kidney-
collecting duct cells and mediate water retention. V3
receptors are found on cells within the central nervous
system and modulate corticotrophin secretion. In septic
shock, treatment is aimed to stimulate V1 receptors, and the
vascular selectivity (V1/V2) of terlipressin is 2.2/1.0
compared with 1.0/1.0 for vasopressin [8].
Initially, terlipressin was used as a substitute for vasopressin.
The difference is their pharmacokinetics [7]. The half-life of
terlipressin is 6 hours compared with 20 minutes for vaso-
pressin. Because of the prolonged half-life of terlipressin,
patients with septic shock received repeated boluses (1 mg)
of the drug [3,4]. After intravenous injection, terlipressin
works as a prodrug that slowly metabolizes to lysine-
vasopressin and in this way provides prolonged biological
effect. Nevertheless, a recent paper shows that terlipressin is
not only a prodrug of vasopressin but also a strong vaso-
constrictor per se [9]. With regard to vasopressin, terlipressin
may by itself have certain specific properties.
Because of its strong vasopressive effects, excessive
vasoconstriction and a decrease in cardiac index are
associated with bolus injection of terlipressin [3-6]. It was
therefore hypothesized that low-dose continuous infusion
may reverse sepsis-related systemic arterial hypotension with
reduced side effects. In an ovine model, continuous infusion
of terlipressin permanently reversed endotoxin-induced
systemic arterial hypotension and improved left ventricular
stroke work, whereas bolus injections were associated with a
decrease in cardiac index and increases in pulmonary
resistance [10].
The purpose of the study by Morelli and colleagues [1] was
to test this hypothesis in humans. They used a fixed low dose
of continuous infusion of terlipressin (1.3 μg/kg per hour,
which is approximately equal to 2 mg/day). This treatment
was associated with a reduced norepinephrine infusion rate
as compared with a control group. This result was not found
in the vasopressin group (0.03 U/minute). However, as the
fixed dosages were compared, this suggests that vasopressin
at 0.03 U/minute probably reduces vasoconstriction less than
terlipressin at 1.3 μg/kg per hour.
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The use of invasive monitoring is one of the strengths of the
study. As compared with norepinephrine, terlipressin did not
impair systemic hemodynamics. However, the persistent low
levels of mixed venous oxygen saturation (SvO2) in all groups
were quite unusual in septic shock. This would indirectly
show that the management of these patients did not follow
recent published guidelines [11]. The investigators should
not be blamed for not following international guidelines, but a
local effect may have a role in their findings. At variance, low-
dose terlipressin seems to have beneficial effects on regional
hemodynamics [12].
One point deserves consideration. Although vasopressin and
analogs are recommended in patients with refractory septic
shock, the investigators chose to introduce them as first-line
treatment. This strategy may in fact be supported by several
lines of evidence. In the Vasopressin and Septic Shock Trial
(VASST), low-dose vasopressin plus norepinephrine was
compared with norepinephrine among patients with septic
shock [13]. Although low-dose vasopressin did not reduce
overall mortality rates, the mortality rate in patients with less
severe septic shock was lower in the vasopressin group than
in the norepinephrine group. These results are consistent
with findings in isolated arteries, in which the ‘beneficial’
synergistic effect of low-dose vasopressin (on norepinephrine
responsiveness) was preserved in conditions mimicking less
severe septic shock but was eliminated in a model of more
severe shock [14]. Hence, one can hypothesize that a
strategy using an early and multimodal approach to
counteract the vascular dysfunction in septic shock may pay
off.
Already, we are waiting for the results of the subsequent
study, entitled Terlipressin in Septic Shock Trial (TESST-1).
This randomized study, a European translation of VASST,
was initiated to assess the safety and efficacy of continuous
low-dose terlipressin infusion to treat patients with septic
shock.
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